Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant

Nature Clinical Practice Oncology

Volumn 4, Issue 8, 2007, Pages 491-495

  Owonikoko, Taofeek ^a   Agha, Mounzer ^a   Balassanian, Ronald ^a   Smith, Ryan ^a   Raptis, Anastasios ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BRAIN METASTASIS; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CLINICAL FEATURE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PRIORITY JOURNAL; STOMATITIS; TONGUE TUMOR;

ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; SARCOMA, GRANULOCYTIC;

EID: 34548587514     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0899     Document Type: Article

References (17)

1. Bekassy AN et al. (1996) Granulocytic sarcoma after allogeneic bone marrow transplantation: A retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 17 801-808
2. Au WY et al. (1999) Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 17: 45-52
3. Ruiz-Arguelles GJ et al. (2005) Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning. Int J Hematol 82: 262-265
4. Simpson DR et al. (1998) High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem call transplantation. Bone Marrow Tansplant 22: 259-264
5. Kara IO et al. (2005) Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma 46: 1081-1084
6. Choi SJ et al. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A high incidence of isolated extramedullary relapse. Leukemia 18: 1789-1797
7. Potenza L et al. (2006) Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: Case report and review of the literature. Am J Hamatol 81: 45-50
8. Lee KH et al. (2003) Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoistic cell transplantation: Risk factors and clinical course. Bone Marrow Transplant 32: 835-842
9. Butcher EC et al. (1997) Lymphocyte homing and homeostasis. Science 272: 60-66
10. Edinger M et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144-1450
11. Tsimberidou AM et al. (2006) The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132: 398-409
12. Larson RA et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442-1452
13. Bross PF et al. (2001) Approval summary: Gemtuzumab, ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490-1496
14. Burnett AK et al. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1,115 patents in the MRC AML15 trial [abstract #13]. Blood 108 (Suppl)
15. Roman E et al. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 11 (Suppl): S7164-S7170
16. Cohen AAD et al. (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30: 23-28
17. Piccaluga PP et al. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 45: 1791-1795